Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model

Patricia L. Earl, Linda S. Wyatt, David C. Montefiori, Miroslawa Bilska, Ruth Woodward, Phillip D. Markham, James D. Malley, Thorsten U. Vogel, Todd M. Allen, David Watkins, Nancy Miller, Bernard Moss

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Rhesus macaques were immunized with a replication-deficient vaccinia virus (MVA) expressing human immunodeficiency virus type 1 89.6 envelope (env) and SIV gagpol (MVA/SHIV89.6) with or without a protein boost consisting of soluble 89.6 env (gp140). Immunization with MVA/SHIV89.6 alone elicited binding antibodies in all animals and neutralizing antibodies in 5 of 15 animals. Both types of antibodies were enhanced by protein boosting. In addition, CD8 cells exhibiting CM9 tetramer binding were detected in the subset of animals that were Mamu-A*01 positive. Animals were challenged intravenously with either SHIV-89.6 (Study 1) or the more pathogenic derivative SHIV-89.6P (Study 2). In Study 1, all control and vaccinated animals except one became infected. However, the levels of viremia were as follows: controls > rMVA alone > rMVA + protein. The differences were statistically significant between immunized and control groups but not between the two immunized groups. In Study 2, all animals became infected; however, the vaccinated group exhibited a 5-fold reduction in peak viremia and a 10-fold reduction in the postacute phase viremia in comparison to the controls. All of the controls required euthanasia by 10 months after challenge. A relationship between vaccine-induced antibody titers and reduction in virus burden was observed in both studies. Thus, immunization with MVA/SHIV89.6 alone or with a protein boost stimulated both arms of the immune system and resulted in significant control of viremia and delayed progression to disease after challenge with SHIV-89.6P.

Original languageEnglish
Pages (from-to)270-281
Number of pages12
JournalVirology
Volume294
Issue number2
DOIs
StatePublished - Sep 2 2002
Externally publishedYes

Fingerprint

Macaca mulatta
Vaccines
Viremia
Proteins
Antibodies
Immunization
Euthanasia
Vaccinia virus
Neutralizing Antibodies
Disease Progression
HIV-1
Immune System
Viruses
Control Groups

Keywords

  • Oligomeric env protein
  • Recombinant modified vaccinia virus Ankara
  • Rhesus macaque
  • SHIV-89.6P
  • SHIV89.6
  • Vaccine

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Earl, P. L., Wyatt, L. S., Montefiori, D. C., Bilska, M., Woodward, R., Markham, P. D., ... Moss, B. (2002). Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model. Virology, 294(2), 270-281. https://doi.org/10.1006/viro.2001.1345

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model. / Earl, Patricia L.; Wyatt, Linda S.; Montefiori, David C.; Bilska, Miroslawa; Woodward, Ruth; Markham, Phillip D.; Malley, James D.; Vogel, Thorsten U.; Allen, Todd M.; Watkins, David; Miller, Nancy; Moss, Bernard.

In: Virology, Vol. 294, No. 2, 02.09.2002, p. 270-281.

Research output: Contribution to journalArticle

Earl, PL, Wyatt, LS, Montefiori, DC, Bilska, M, Woodward, R, Markham, PD, Malley, JD, Vogel, TU, Allen, TM, Watkins, D, Miller, N & Moss, B 2002, 'Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model', Virology, vol. 294, no. 2, pp. 270-281. https://doi.org/10.1006/viro.2001.1345
Earl, Patricia L. ; Wyatt, Linda S. ; Montefiori, David C. ; Bilska, Miroslawa ; Woodward, Ruth ; Markham, Phillip D. ; Malley, James D. ; Vogel, Thorsten U. ; Allen, Todd M. ; Watkins, David ; Miller, Nancy ; Moss, Bernard. / Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model. In: Virology. 2002 ; Vol. 294, No. 2. pp. 270-281.
@article{c8d56b726ddf495e90249c58d9a5e9b5,
title = "Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model",
abstract = "Rhesus macaques were immunized with a replication-deficient vaccinia virus (MVA) expressing human immunodeficiency virus type 1 89.6 envelope (env) and SIV gagpol (MVA/SHIV89.6) with or without a protein boost consisting of soluble 89.6 env (gp140). Immunization with MVA/SHIV89.6 alone elicited binding antibodies in all animals and neutralizing antibodies in 5 of 15 animals. Both types of antibodies were enhanced by protein boosting. In addition, CD8 cells exhibiting CM9 tetramer binding were detected in the subset of animals that were Mamu-A*01 positive. Animals were challenged intravenously with either SHIV-89.6 (Study 1) or the more pathogenic derivative SHIV-89.6P (Study 2). In Study 1, all control and vaccinated animals except one became infected. However, the levels of viremia were as follows: controls > rMVA alone > rMVA + protein. The differences were statistically significant between immunized and control groups but not between the two immunized groups. In Study 2, all animals became infected; however, the vaccinated group exhibited a 5-fold reduction in peak viremia and a 10-fold reduction in the postacute phase viremia in comparison to the controls. All of the controls required euthanasia by 10 months after challenge. A relationship between vaccine-induced antibody titers and reduction in virus burden was observed in both studies. Thus, immunization with MVA/SHIV89.6 alone or with a protein boost stimulated both arms of the immune system and resulted in significant control of viremia and delayed progression to disease after challenge with SHIV-89.6P.",
keywords = "Oligomeric env protein, Recombinant modified vaccinia virus Ankara, Rhesus macaque, SHIV-89.6P, SHIV89.6, Vaccine",
author = "Earl, {Patricia L.} and Wyatt, {Linda S.} and Montefiori, {David C.} and Miroslawa Bilska and Ruth Woodward and Markham, {Phillip D.} and Malley, {James D.} and Vogel, {Thorsten U.} and Allen, {Todd M.} and David Watkins and Nancy Miller and Bernard Moss",
year = "2002",
month = "9",
day = "2",
doi = "10.1006/viro.2001.1345",
language = "English",
volume = "294",
pages = "270--281",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model

AU - Earl, Patricia L.

AU - Wyatt, Linda S.

AU - Montefiori, David C.

AU - Bilska, Miroslawa

AU - Woodward, Ruth

AU - Markham, Phillip D.

AU - Malley, James D.

AU - Vogel, Thorsten U.

AU - Allen, Todd M.

AU - Watkins, David

AU - Miller, Nancy

AU - Moss, Bernard

PY - 2002/9/2

Y1 - 2002/9/2

N2 - Rhesus macaques were immunized with a replication-deficient vaccinia virus (MVA) expressing human immunodeficiency virus type 1 89.6 envelope (env) and SIV gagpol (MVA/SHIV89.6) with or without a protein boost consisting of soluble 89.6 env (gp140). Immunization with MVA/SHIV89.6 alone elicited binding antibodies in all animals and neutralizing antibodies in 5 of 15 animals. Both types of antibodies were enhanced by protein boosting. In addition, CD8 cells exhibiting CM9 tetramer binding were detected in the subset of animals that were Mamu-A*01 positive. Animals were challenged intravenously with either SHIV-89.6 (Study 1) or the more pathogenic derivative SHIV-89.6P (Study 2). In Study 1, all control and vaccinated animals except one became infected. However, the levels of viremia were as follows: controls > rMVA alone > rMVA + protein. The differences were statistically significant between immunized and control groups but not between the two immunized groups. In Study 2, all animals became infected; however, the vaccinated group exhibited a 5-fold reduction in peak viremia and a 10-fold reduction in the postacute phase viremia in comparison to the controls. All of the controls required euthanasia by 10 months after challenge. A relationship between vaccine-induced antibody titers and reduction in virus burden was observed in both studies. Thus, immunization with MVA/SHIV89.6 alone or with a protein boost stimulated both arms of the immune system and resulted in significant control of viremia and delayed progression to disease after challenge with SHIV-89.6P.

AB - Rhesus macaques were immunized with a replication-deficient vaccinia virus (MVA) expressing human immunodeficiency virus type 1 89.6 envelope (env) and SIV gagpol (MVA/SHIV89.6) with or without a protein boost consisting of soluble 89.6 env (gp140). Immunization with MVA/SHIV89.6 alone elicited binding antibodies in all animals and neutralizing antibodies in 5 of 15 animals. Both types of antibodies were enhanced by protein boosting. In addition, CD8 cells exhibiting CM9 tetramer binding were detected in the subset of animals that were Mamu-A*01 positive. Animals were challenged intravenously with either SHIV-89.6 (Study 1) or the more pathogenic derivative SHIV-89.6P (Study 2). In Study 1, all control and vaccinated animals except one became infected. However, the levels of viremia were as follows: controls > rMVA alone > rMVA + protein. The differences were statistically significant between immunized and control groups but not between the two immunized groups. In Study 2, all animals became infected; however, the vaccinated group exhibited a 5-fold reduction in peak viremia and a 10-fold reduction in the postacute phase viremia in comparison to the controls. All of the controls required euthanasia by 10 months after challenge. A relationship between vaccine-induced antibody titers and reduction in virus burden was observed in both studies. Thus, immunization with MVA/SHIV89.6 alone or with a protein boost stimulated both arms of the immune system and resulted in significant control of viremia and delayed progression to disease after challenge with SHIV-89.6P.

KW - Oligomeric env protein

KW - Recombinant modified vaccinia virus Ankara

KW - Rhesus macaque

KW - SHIV-89.6P

KW - SHIV89.6

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0036056987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036056987&partnerID=8YFLogxK

U2 - 10.1006/viro.2001.1345

DO - 10.1006/viro.2001.1345

M3 - Article

C2 - 12009868

AN - SCOPUS:0036056987

VL - 294

SP - 270

EP - 281

JO - Virology

JF - Virology

SN - 0042-6822

IS - 2

ER -